Be the first to like.

Share

Humira, a treatment for inflammatory diseases such as rheumatoid arthritis and psoriasis made by AbbVie Inc., is the planet’s best-selling drug. It’s also been around almost 15 years. Those two facts alone would normally have rival drugmakers eagerly circling, ready to roll out generic versions that could win a piece of the aging medicine’s $16 billion in annual sales. Yet last year, when the patent on Humira’s main ingredient expired, not a single competitor launched a copycat version. Figuring out how to manufacture it wasn’t the obstacle. The real challenge was the seemingly impregnable fortress of patents AbbVie has methodically constructed around its prized moneymaker.

… Read More

Image: By Black Stripe at English Wikipedia, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=26581981

Be the first to like.

Share
Bloomberg Businessweek

Tags: , , , , , , , ,

Leave a Reply